miR-124-3p combined with miR-506-3p delay hepatic carcinogenesis via modulating sirtuin 1

References

• Bae, H.J., et al., 2014. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene, 33 (20), 2557–2567.
   PubMed Web of Science ®Google Scholar
• Bartolini, D., et al., 2018. Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. Translational research: the journal of laboratory and clinical medicine, 193, 54–71.
   PubMed Web of Science ®Google Scholar
• Bray, F., et al., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68 (6), 394–424.
   PubMed Web of Science ®Google Scholar
• Chen, J., et al., 2011. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer research, 71 (12), 4138–4149.
   PubMed Web of Science ®Google Scholar
• Chen, W., et al., 2016. Cancer statistics in China, 2015. CA: a cancer journal for clinicians, 66, 115–132.
   PubMed Web of Science ®Google Scholar
• Chen, X., et al., 2019. Deacetylation of β-catenin by SIRT1 regulates self-renewal and oncogenesis of liver cancer stem cells. Cancer letters, 463, 1–10.
   PubMed Web of Science ®Google Scholar
• Chun, S.K., et al., 2018. Loss of sirtuin 1 and mitofusin 2 contributes to enhanced ischemia/reperfusion injury in aged livers. Aging cell, 17 (4), e12761.
   PubMed Web of Science ®Google Scholar
• Cui, R.-J., et al., 2019. miR-124-3p availability is antagonized by LncRNA-MALAT1 for Slug-induced tumor metastasis in hepatocellular carcinoma. Cancer medicine, 8 (14), 6358–6369.
   PubMed Web of Science ®Google Scholar
• Farcas, M., et al., 2019. SIRT1 in the development and treatment of hepatocellular carcinoma. Frontiers in nutrition, 6, 148–148.
   PubMed Web of Science ®Google Scholar
• Feng, R.-M., et al., 2019. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer communications, 39 (1), 22–22.
   PubMed Web of Science ®Google Scholar
• Frazzi, R., 2018. SIRT1 in secretory organ cancer. Frontiers in endocrinology, 9, 569–569.
   PubMed Web of Science ®Google Scholar
• Guo, S., et al., 2017. Genetic and epigenetic silencing of mircoRNA-506-3p enhances COTL1 oncogene expression to foster non-small lung cancer progression. Oncotarget, 8 (1), 644–657.
   PubMedGoogle Scholar
• Hu, C.Y., et al., 2019. MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4. European review for medical and pharmacological sciences, 23 (12), 5133–5138.
   PubMed Web of Science ®Google Scholar
• Jiashi, W., et al., 2018. MicroRNA-506-3p inhibits osteosarcoma cell proliferation and metastasis by suppressing RAB3D expression. Aging, 10 (6), 1294–1305.
   PubMedGoogle Scholar
• Karbasforooshan, H., Roohbakhsh, A., and Karimi, G., 2018. SIRT1 and microRNAs: the role in breast, lung and prostate cancers. Experimental cell research, 367 (1), 1–6.
   PubMed Web of Science ®Google Scholar
• Klingenberg, M., et al., 2017. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. Journal of hepatology, 67 (3), 603–618.
   PubMed Web of Science ®Google Scholar
• Li, H., et al., 2020. Long noncoding RNA SNHG17 induced by YY1 facilitates the glioma progression through targeting miR-506-3p/CTNNB1 axis to activate Wnt/β-catenin signaling pathway. Cancer cell international, 20, 29–29.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2014. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell stem cell, 15 (4), 431–446.
   PubMed Web of Science ®Google Scholar
• Liang, T.-S., et al., 2019. MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/β-catenin signaling pathway by down-regulating LHX2. Journal of experimental & clinical cancer research, 38 (1), 97–97.
   PubMed Web of Science ®Google Scholar
• Lin, C.-Y., et al., 2019. Engagement with tNOX (ENOX2) to inhibit SIRT1 and activate p53-dependent and -independent apoptotic pathways by novel 4,11-diaminoanthra[2,3-b]furan-5,10-diones in hepatocellular carcinoma cells. Cancers, 11 (3), 420.
   PubMed Web of Science ®Google Scholar
• Liu, L., et al., 2016a. SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells. Hepatology, 64 (3), 814–827.
   PubMed Web of Science ®Google Scholar
• Liu, Z., et al., 2016b. Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. Oncotarget, 7 (18), 25350–25365.
   PubMedGoogle Scholar
• Livak, K.J., and Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods, 25 (4), 402–408.
   PubMed Web of Science ®Google Scholar
• Long, H.-D., et al., 2018. Reduced hsa-miR-124-3p levels are associated with the poor survival of patients with hepatocellular carcinoma. Molecular biology reports, 45 (6), 2615–2623.
   PubMed Web of Science ®Google Scholar
• Longo, V.D. and Kennedy, B.K., 2006. Sirtuins in aging and age-related disease. Cell, 126 (2), 257–268.
   PubMed Web of Science ®Google Scholar
• Purushotham, A., et al., 2009. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell metabolism, 9 (4), 327–338.
   PubMed Web of Science ®Google Scholar
• Qi, Y., Yao, X., and Du, X., 2020. Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1. IUBMB life, 72 (3), 452–464.
   PubMed Web of Science ®Google Scholar
• Singh, A.K., Kumar, R., and Pandey, A.K., 2018. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Current chemical genomics and translational medicine, 12, 9–26.
   PubMedGoogle Scholar
• Toh, T.B., Lim, J.J., and Chow, E.K.-H., 2019. Epigenetics of hepatocellular carcinoma. Clinical and translational medicine, 8 (1), 13–13.
   PubMedGoogle Scholar
• Wang, Y., et al., 2016. SIRT1 increases YAP- and MKK3-dependent p38 phosphorylation in mouse liver and human hepatocellular carcinoma. Oncotarget, 7 (10), 11284–11298.
   PubMedGoogle Scholar
• Wong, C.-M., Tsang, F.H.-C., and Ng, I.O.-L., 2018. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nature reviews. Gastroenterology & hepatology, 15 (3), 137–151.
   PubMed Web of Science ®Google Scholar
• Yao, Z.-Q., et al., 2018. A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma. Cell death & disease, 9 (7), 767–767.
   PubMedGoogle Scholar
• Zhang, H., et al., 2020. MicroRNA-490-3p suppresses hepatocellular carcinoma cell proliferation and migration by targeting the aurora kinase A gene (AURKA). Archives of medical science, 16 (2), 395–406.
   PubMed Web of Science ®Google Scholar